Table 3.
CAR-NK clinical trials for lymphoma
| Target Antigen | Tumor Type | Type of NK Cell | Phase | NCT Number | Status | Country |
|---|---|---|---|---|---|---|
| CD19 | NHL | Not Listed | Early Phase I | NCT04639739 | Not yet recruiting | China |
| CD19 | ALL, CLL, Mantle Cell and Follicular Lymphoma | NK-92 | Phase I/II | NCT02892695 | Unknown | China |
| CD19 | ALL, NHL, CLL | Cord Blood | Phase I | NCT04796675 | Recruiting | China |
| CD19 | ALL, NHL, CLL | Cord Blood | Phase I/II | NCT03056339 | Recruiting | USA |
| CD19 | ALL, CLL, B Cell Lymphoma | Cord Blood | Phase I | NCT04796688 | Recruiting | China |
| CD19 | B cell lymphoma, Mantle cell and Follicular Lymphoma | Cord Blood | Phase I/II | NCT03579927 | Withdrawn | USA |
| CD19 | B Cell Lymphoma, CLL | iPSC | Phase I | NCT04245722 | Recruiting | USA |
| CD19 | B Cell Lymphoma | Not Listed | Early Phase I | NCT03690310 | Not yet recruiting | China |
| CD19/CD22 | B cell Lymphoma | Not Listed | Early Phase I | NCT03824964 | Unknown | China |
| CD22 | B Cell Lymphoma | Not Listed | Early Phase I | NCT03692767 | Not yet recruiting | China |
| CD7 | AML, T-ALL, T-LLy, NK/T-LLy | NK-92 | Phase I/II | NCT02742727 | Unknown | China |
CAR chimeric antigen receptor, NK natural killer, NCT national clinical trial, NHL non-Hodgkin lymphoma, AML acute myelogenous leukemia, ALL acute lymphoblastic leukemia, LLy lymphoblastic lymphoma, CLL chronic lymphocytic leukemia